Abstract
BackgroundGenetically modified mosquitoes have been proposed as an alternative strategy to reduce the heavy burden of malaria. In recent years, several proof-of-principle experiments have been performed that validate the idea that mosquitoes can be genetically modified to become refractory to malaria parasite development.ResultsWe have created two transgenic lines of Anopheles stephensi , a natural vector of Plasmodium falciparum, which constitutively secrete a catalytically inactive phospholipase A2 (mPLA2) into the midgut lumen to interfere with Plasmodium ookinete invasion. Our experiments show that both transgenic lines expressing mPLA2 significantly impair the development of rodent malaria parasites, but only one line impairs the development of human malaria parasites. In addition, when fed on malaria-infected blood, mosquitoes from both transgenic lines are more fecund than non-transgenic mosquitoes. Consistent with these observations, cage experiments with mixed populations of transgenic and non-transgenic mosquitoes show that the percentage of transgenic mosquitoes increases when maintained on Plasmodium -infected blood.ConclusionsOur results suggest that the expression of an anti-Plasmodium effector gene gives transgenic mosquitoes a fitness advantage when fed malaria-infected blood. These findings have important implications for future applications of transgenic mosquito technology in malaria control.
Highlights
The ability to genetically modify mosquito vectors of malaria continues to be an attractive approach to malaria control
To investigate whether a transgene that limits P. falciparum development could confer a selective advantage when expressed from its natural vector, we developed transgenic An. stephensi that express a catalytically inactive phospholipase gene under the control of a constitutive midgut promoter
Our data demonstrate that transgenic An. stephensi mosquitoes expressing a mutant PLA2 construct under the control of a constitutively active midgut promoter can impair both P. berghei and P. falciparum development
Summary
The ability to genetically modify mosquito vectors of malaria continues to be an attractive approach to malaria control. Effector proteins, and methods to increase the mosquito immune response have each been utilized to confer anti-Plasmodium resistance in proof-of-principle laboratory experiments for malaria transmission [1,2,3,4] This approach has been further validated with the human malaria parasite, P. falciparum, to impair transmission using the natural host-pathogen combination [5,6,7,8]. Conclusions: Our results suggest that the expression of an anti-Plasmodium effector gene gives transgenic mosquitoes a fitness advantage when fed malaria-infected blood. These findings have important implications for future applications of transgenic mosquito technology in malaria control
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.